Dolnoslaskie Centrum Onkologii Pulmonologii I Hematologii — Clinical Trial Site

77 Registered trials

31 Currently recruiting

Organisation

Dolnoslaskie Centrum Onkologii Pulmonologii I Hematologii

Location

Wroclaw, Poland

Identifier

ORG-100040903

Address

Ul. Grabiszynska 105, 53-439, Poland

Departments

#048003: Poradnia Leczenia Nowotworów Piersi
#8005; Oddzial Hematologiczny
5707:Specjalistyczna Przychodnia Onkologiczna, Poradnia Chemioterapii, Leczenia Nowotworw Piersi
Breast Unit
Centrum Hematologiczno - Transplantacyjne
Centrum Hematologiczno-Transplantacyjne
Clinical Trials Unit
Department of Clinical Oncology
Department of Oncology and Oncological Gynecology
III Klinika Radioterapii i Chemioterapii
n/a
NA
Oddzial Chirurgii Onkologicznej II - Urologia
Oddzial Hematologiczny
Oddzial Onkologii Klinicznej
Oddzial Onkologii Klinicznej / Chemioterapii Leczenie Skojarzone – Chemioterapia Dzienna
Oddzial Onkologii/Chemioterapii
Oddzial PL011: Onkologii Klinicznej/Chemioterapii
Oddział Chirurgii Onkologicznej II
Oddział Chemioterapii Dziennej
Oddział Chirurgii II – Pododdział Urologii
Oddział Chirurgii Nowotworów Przewodu Pokarmowego
Oddział Chirurgii Onkologicznej I
Oddział Chirurgii Onkologicznej II- Urologia
Oddział chirurgii onkologicznej II, Pododdział Urologii
Oddział Chirurgii Piersi
Oddział dzienny Onkologii Klinicznej – Breast Unit
Oddział Ginekologii Onkologicznej
Oddział Hematologiczny
Oddział Hematologiczny, Transplantologiczny oraz Immunologii Klinicznej
Oddział Nowotworów Tkanek Miękkich, Skóry i Czerniaków
Oddział Nowotworu Piersi
Oddział Onkologii Klinicznej
Oddział Onkologii Klinicznej (Chemioterapii)
Oddział Onkologii Klinicznej (Nowotworów Klatki Piersiowej)
Oddział Onkologii Klinicznej / Chemioterapii
Oddział Onkologii Klinicznej /Chemioterapii
Oddział Onkologii Klinicznej i Chemioterapii
Oddział Onkologii Klinicznej VII
Oddział Onkologii Klinicznej/ Chemioterapi
Oddział Onkologii Klinicznej/Chemioterapii
Oddział Onkologii/ Chemioterapii
Oddział Urologii
Oddział Urologii Onkologicznej
Odział Onkologii Klinicznej
Oncology
Osrodek Badan Klinicznych Wczesnych Faz
Pododdzial Chirurgii II -Urologia
Pododdzial Urologii
Pododział Urologii
Poradnia Chemioterapii
Poradnia Chemioterapii - Leczenie Nowotworów Piers
Urology
Zaklad Radioterapii

Clinical trials at this site (77)

Search interface

A trial to learn how well Dato-DXd works and how safe it is compared to standard chemotherapy in adults with triple-negative breast cancer (… Ended

2023-509260-25-00 Locally Recurrent Inoperable or Metastatic Triple-negat 5 2022-07-12
A Multi Arm Study in Participants with MSI-High Metastatic Colorectal Cancer Ended

2022-502100-70-00 Participants with Microsatellite Instability-High (MSI- 10 2021-06-23
A Study to Evaluate Effects of Atezolizumab (anti-PD-L1 antibody) as an Adjuvant Therapy in Patients with High-Risk Muscle-invasive Bladder … Ended

2022-502705-15-00 High-risk muscle-invasive bladder cancer 5 2021-03-08
Study of Trastuzumab Deruxtecan (DS-8201a, T-DXd) versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Ca… Ended

2024-516653-44-00 HER2-Low, Hormone Receptor Positive Breast Cancer which 5 2020-11-30
A Study of Atezolizumab with or without Tiragolumab in Participants with Unresectable Esophageal Squamous Cell Carcinoma whose Cancers have … Ended

2022-502052-30-00 Unresectable Esophageal Squamous Cell Carcinoma 5 2020-10-27
An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizu… Ended

2023-506184-34-00 Advanced Malignancies 5 2019-08-09
A study of androgen deprivation therapy (ADT) plus apalutamide in patients with prostate cancer Ended

2023-506153-38-00 High-risk localized or locally advanced prostate cancer 5 2019-07-11
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea… Ended

2023-510357-42-00 hormone receptor (HR)-positive, HER2-negative, early br 5 2019-05-22
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Foll… Ended

2023-509602-29-00 Patients with Limited Stage Small-Cell Lung Cancer (LS- 5 2019-02-11
This is a Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatmen… Ended

2023-510015-19-00 Patients with histologically or cytologically documente 5 2019-02-11
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treat… Ended

2024-513912-89-00 Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofi 10 2018-12-13
Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended

2023-504820-24-00 Neoadjuvant/Adjuvant treatment for participants with Re 5 2018-03-21
A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combinatio… Ended

2024-514205-60-00 Triple Negative Breast Cancer 4 2018-02-15
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended

2023-509671-17-00 Breast Cancer 5 2017-07-12
CheckMate 274 Ended

2022-500630-29-00 Subjects with High Risk Invasive Urothelial Carcinoma 5 2016-05-06
A Study of Eciskafusp Alfa and Bacillus Calmette-Guérin (BCG) in Participants with High-Risk Bladder Cancer Unresponsive to BCG Treatment Ended

2024-515410-41-00 BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder 9 2025-04-01
A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i… Ended

2023-506696-10-00 Non-Small Cell Lung Cancer 5 2024-06-18
A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myelo… Ended

2023-505910-10-00 Relapsed or Refractory High-Risk Myelodysplastic Syndro 4 2024-01-23
Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended

2022-502196-31-00 Advanced or Recurrent Endometrial Cancer 10 2023-08-21
Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome Ended

2024-511922-30-00 Carcinoid Syndrome 4 2023-05-11
Efficacy and safety of obinutuzumab versus rituximab in combination with chemotherapy for adult patients with newly diagnosed CD20-positive … Ended

2024-517389-40-00 acute lymphoblastic leukemia 4 2021-10-06
Preoperative intraperitoneal chemotherapy in adjuvant hyperthermia adjunctive therapy in advanced gastric cancer with high-risk of peritonea… Ended

2024-516042-18-00 Gastric Carcinoma 10 2021-09-08
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Ga… Ended

2023-504834-23-00 Advanced/Metastatic Gastroesophageal Adenocarcinoma 11 2021-02-24
A Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination with Cabozantinib Versus Cabozantinib Alone in Patients wit… Ended

2024-517785-42-00 Renal cell carcinoma (RCC) 5 2020-10-08